What is Halozyme?
Halozyme Inc. operates at the intersection of biotechnology and advanced pharmaceutical engineering. The company is primarily recognized for its proprietary ENHANZE technology, which facilitates the subcutaneous administration of biologic medicines that traditionally require intravenous infusion. By enabling this shift in drug delivery, Halozyme significantly improves patient experience and clinical efficiency. The organization maintains a robust business model that integrates internal therapeutic development with high-value licensing agreements. This dual-pronged approach allows the company to capture revenue through royalties and collaborative partnerships with major pharmaceutical entities, positioning it as a critical infrastructure provider within the modern healthcare ecosystem. Its focus on enzyme-based therapeutic solutions has established a defensible market position, characterized by long-term commercial agreements and a growing portfolio of integrated biologic therapies.
How much funding has Halozyme raised?
Halozyme has raised a total of $1.1B across 10 funding rounds:
Corporate Investment
$5.5M
Stock Offering
$38.2M
Stock Offering
$60M
Stock Offering
$81.8M
Debt
$50M
Stock Offering
$107.8M
Debt
$150M
Stock Offering
$135M
Debt
$400M
Corporate Investment (2009): $5.5M led by Baxter Healthcare Corporation
Stock Issuance/Offering (2009): $38.2M supported by Undisclosed
Stock Issuance/Offering (2010): $60M featuring Undisclosed
Stock Issuance/Offering (2012): $81.8M backed by Undisclosed
Debt (2014): $50M with participation from Oxford Finance and Silicon Valley Bank
Stock Issuance/Offering (2014): $107.8M led by Undisclosed
Debt (2016): $150M supported by Pharmakon Advisors and Athyrium Capital Management
Stock Issuance/Offering (2017): $135M featuring Undisclosed
Debt (2019): $400M backed by Undisclosed
Key Investors in Halozyme
Oxford Finance
Oxford Finance is a specialty finance firm that provides flexible capital solutions tailored to the unique needs of healthcare and life sciences companies.
Silicon Valley Bank
A cornerstone of the innovation economy, SVB provides specialized banking, asset management, and financial services to high-growth technology and life science enterprises.
Athyrium Capital Management
Athyrium Capital Management is a leading investment platform focused on structured financing and equity investments within the global healthcare and biotechnology sectors.
What's next for Halozyme?
With the infusion of $400M, Halozyme is well-positioned to accelerate its R&D initiatives and expand the clinical utility of its delivery platforms. The company's strategic roadmap likely involves deepening its existing pharmaceutical collaborations while exploring new therapeutic areas where subcutaneous delivery can provide a competitive advantage. As the biotechnology industry shifts toward more patient-centric care models, Halozyme's ability to streamline complex drug administration will remain a key driver of its long-term growth. Investors and industry analysts will be monitoring the company's ability to convert its pipeline of licensed technologies into sustained royalty streams, ensuring that the firm maintains its leadership in the biopharmaceutical delivery space.
See full Halozyme company page
